stockrowTarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024.
- Revenue
- +63.9%
- EPS
- −4,699.1%
- Free cash flow
- −144.1%
- Total debt
- +0.90%
Quarter to September 2026, against a year earlier
Follow TARS
Alert me
Tarsus Pharmaceuticals, Inc. (TARS) EPS (diluted)
Tarsus Pharmaceuticals, Inc.'s EPS (diluted) for fiscal 2025 was −$1.59, compared with −$3.07 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$15.19. Over the past ten years it has ranged from −$4.62 (fiscal 2023) to −$0.07 (fiscal 2018); the current reading is higher than 75% of that period. Tarsus Pharmaceuticals, Inc. ranks 518th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.59 | — |
| FY2024 | −$3.07 | — |
| FY2023 | −$4.62 | — |
| FY2022 | −$2.52 | — |
| FY2021 | −$0.67 | — |
| FY2020 | −$4.32 | — |
| FY2019 | −$1.98 | — |
| FY2018 | −$0.07 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$14.40 | — |
| Jun 2026 | −$0.43 | — |
| Mar 2026 | −$0.16 | — |
| Dec 2025 | −$0.20 | — |
| 24 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $2.11 |
| ELVN Enliven Therapeutics, Inc. compare | −$1.67 |
| DNLI Denali Therapeutics Inc. compare | −$1.73 |
| DYN Dyne Therapeutics, Inc. compare | −$3.33 |
| VRDN Viridian Therapeutics, Inc. compare | −$3.37 |
| CELC Celcuity, Inc. compare | −$4.30 |
| VKTX Viking Therapeutics, Inc. compare | −$5.40 |
| TARS Tarsus Pharmaceuticals, Inc. | −$15.19 |
| TLX Telix Pharmaceuticals Limited compare | — |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on TARS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement